Clinical Trial

A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease

Study acronym: VacSYn
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety, tolerability, immunogenicity, and pharmacodynamic effects of ACI-7104.056 in patients with early stages of Parkinson's disease.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-08-22; most recent amendment 2025-11-18.
Status change: Recruiting → Active, Not Recruiting 2025-11-18
Trial Details
NCT Number NCT06015841
Lead Sponsor AC Immune SA
Collaborators: ICON Clinical Research
Conditions Parkinson Disease, Parkinson Disease 6, Early-Onset
Enrollment 150 participants
Start Date 2023-07-24
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2025-11-21